Today's Date: June 4, 2023
Research Results from Ontada HOPE Studies Presented at ASCO 2023 Illuminate How Social Determinants of Health Impact Different P   •   Dorsett Wanchai Marks World Environment Day 2023 with Bold Paperless and Plastic-Free Sustainability Initiatives   •   Nucleai and Mayo Clinic BioPharma Diagnostics Announce Strategic Collaboration to Transform Digital Pathology for Drug Developme   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   Reigniting the Cancer Moonshot: Massive Bio Joins CancerX as Founding Member to Accelerate Innovation and AI Implementation in C   •   Cupshe Celebrates 8th Birthday with Exclusive Collection in Collaboration with Chanel Iman, Heather Rae El Moussa, and Brittany   •   Government of Canada releases summary of actions taken to address the safety and wellbeing of Indigenous women, girls and 2SLGBT   •   Bijou Ikli named new CEO by Florida Assisted Living Association   •   Promising Data for Investigational Innovative Bispecific Ivonescimab Featured at ASCO 2023   •   High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy   •   Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam   •   Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclit   •   Statement by the Prime Minister on Canadian Armed Forces Day   •   TAGRISSO® achieved unprecedented survival in early-stage EGFR-mutated lung cancer, with 88% of patients alive at five years   •   New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing   •   GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting   •   Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipili   •   Tips for a smooth transition to senior living from the San Luis Obispo assisted living professionals   •   ELAHERE® Demonstrates 35% Reduction in the Risk of Disease Progression or Death Versus Chemotherapy in FRα-Positive Pl   •   Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin
Bookmark and Share

Direct Biologics Announces Initiation of Phase 1 Clinical Trial for Medically Refractory Crohn’s Disease

AUSTIN, Texas , March 21 /Businesswire/ - Direct Biologics, LLC, a late-stage biotechnology company leveraging its regenerative medicine platform using extracellular vesicles (EVs) derived from bone marrow mesenchymal stem cells (MSCs) to address multiple disease indications, announced it has dosed the first patient in its Phase 1 clinical trial evaluating ExoFlo for the treatment of patients with medically refractory Crohn’s disease.

“We are excited to announce the initiation of our Crohn’s disease clinical trial as we expand our ExoFlo clinical development program into inflammatory bowel disease,” said Amy Lightner, M.D., Chief Medical Officer of Direct Biologics. “Crohn’s disease is a debilitating lifelong condition that affects every aspect of daily life. With this new trial of ExoFlo, we are seeking to further illustrate the potential anti-inflammatory, immunomodulatory and regenerative properties of ExoFlo, each of which we believe to be crucial in the treatment of Crohn’s disease.”

The open-label Phase 1 clinical trial (NCT05130983) is designed to evaluate the safety and efficacy of ExoFlo for the treatment of medically refractory Crohn’s disease. The trial is expected to enroll 10 patients between the ages of 18 and 75 who have been diagnosed with medically refractory moderate-to-severe Crohn’s disease of at least six months duration and have failed at least one monoclonal antibody therapy. The trial will randomize the 10 patients to two treatment arms. One arm will receive intravenous ExoFlo monthly, and the other arm will receive intravenous ExoFlo every other month.

The primary objective for this trial is to ensure safety in this patient population by recording any adverse or serious adverse events. The secondary objective is to evaluate the efficacy of intravenous ExoFlo in inducing clinical response, clinical and endoscopic remission, and improving disease-specific, health-related quality of life. The trial will measure changes in laboratory values including C-reactive protein and fecal calprotectin, validated clinical scores, validated endoscopic scores, and validated patient survey scores, among others.

About Crohn’s Disease

Crohn’s disease is an idiopathic chronic inflammatory disease of the intestinal tract, which continues to increase in incidence for unknown reasons, resulting in a significant burden to the healthcare system. Crohn’s disease is characterized by transmural inflammation of the intestinal wall which can result in inflammatory, fibrostenosing or penetrating disease of the intestinal tract. This results in patients experiencing chronic abdominal pain, flares resulting in hospitalization or change in medications, and risk of surgical intervention. Despite the ever-growing armamentarium of immunosuppressive medications available, up to 70% of patients still undergo an intestinal resection for medically refractory disease. This current treatment paradigm presents significant potential side effects from approved medications, morbidity with frequent hospitalizations, risk with recurrent intestinal operations, and significantly impaired quality of life in thousands of patients.

About Direct Biologics

Direct Biologics is a late-stage biotechnology company leveraging a regenerative medicine platform which uses extracellular vesicles (EVs) secreted from mesenchymal stem cells to address multiple disease indications. Direct Biologics’ mission is to be the global leader in regenerative medicine through discovery, innovation, advancement of science, and treatment of patients in a safe and effective manner. Our therapeutic product candidate, ExoFlo, is designed to be a scalable, reproducible, and effective next-generation biologic that leverages our proprietary EV platform technology designed to reduce inflammation, modulate the immune system, and restore tissue through cellular regeneration. Direct Biologics is currently conducting the global Phase 3 EXTINGUISH clinical trial of ExoFlo for the treatment of hospitalized adults with Acute Respiratory Distress Syndrome (ARDS) due to COVID-19. In addition, the Company has initiated Phase 1 clinical trials with ExoFlo for the treatment of ulcerative colitis and Crohn’s disease, and expanded access trials in solid abdominal organ transplantation, and severe COVID-19 ARDS patients. Direct Biologics intends to pursue additional clinical applications including all-cause ARDS, perianal fistulizing Crohn’s disease, and necrotizing enterocolitis. Headquartered in Austin, Texas, Direct Biologics also has an R&D facility at the Center for Novel Therapeutics on the campus of University of California at San Diego, and operations and order-fulfillment center in San Antonio, Texas. For more information, please visit and follow us on Twitter @directbiologics.

STORY TAGS: United States, North America, Science, Stem Cells, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Texas, Product/Service,


White House Live Stream
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News